Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What you said. Intelligent people understand where this is going. Know what you own. DYODD
Dilution is not a major concern with previously announced convertible note extension agreements and lock-up agreements. Company is planning to up list to Nasdaq CM and the 1-10 (up to) 1-100 RS will enable this.
It still has to be voted for and enacted with shareholder approval. Voting shareholders will do what's best for the company. It's possible Todos Medical would not survive going forward without this action so, you have to choose the lesser of the two evils. IMHO
https://investor.todosmedical.com/news-events/press-releases/detail/38/todos-medical-announces-legacy-convertible-note-extension
REHOVOT, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into convertible note extension agreements and lock-up agreements with certain institutional investors who participated in the Company’s previously announced $1.35M financing round in Q1 2019 (the ‘2019 Bridge Financing’). All remaining investors who participated in the 2019 Bridge Financing have agreed to extend the maturity of those notes until mid-August 2020 and have entered into lock-up agreements with the Company that preclude them from selling common shares in the market until mid-August 2020
Stop sign should be on the way out too.
Next catalyst will be the filing of Nevada SOS. They do need to bring in something of value and get the share count settled. Still a bottom play for believers.
$TOMDF #goals Great year for Todos Medical. Things coming together fast ???? chart looks good.
Image;
$TOMDF #goals Great year for Todos Medical. Things coming together fast 👊🏻 chart looks good. pic.twitter.com/HBV1qvkjzr
— Randylus (@randylus) April 18, 2020
$TOMDF Lauren Chung
Independent Director, Compensation Committee Member, Nominating Committee Member of Pharmaceutical Holding Corp. now on the board of Todos Medical. Perfect fit. Dr. Chung serves on the business review board of Alzheimer’s Drug Discovery Foundation. #Alzheimers
Images;
$TOMDF Lauren Chung
— Randylus (@randylus) April 18, 2020
Independent Director, Compensation Committee Member, Nominating Committee Member of $CURR now on the board of Todos Medical. Perfect fit. Dr. Chung serves on the business review board of Alzheimer’s Drug Discovery Foundation. #Alzheimers pic.twitter.com/O95DXhWzZ7
$TOMDF Currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Orot has a proven track record of over 3 decades developing breakthrough technologies which will significantly impact cancer care.
$TOMDF Currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Orot has a proven track record of over 3 decades developing breakthrough technologies which will significantly impact cancer care. pic.twitter.com/nIav0OwWw0
— Randylus (@randylus) April 16, 2020
$TOMDF #breastcancer
finance.yahoo.com/news/todos-med…
The Company has continued to advance its ongoing European pre-commercial breast cancer clinical trial in Romania investigating our proprietary TBIA spectroscopy platform using Fourier Transformed Infrared Analysis (FTIR).
$TOMDF #breastcancer https://t.co/cIo8np9bLZ
— Randylus (@randylus) April 17, 2020
The Company has continued to advance its ongoing European pre-commercial breast cancer clinical trial in Romania investigating our proprietary TBIA spectroscopy platform using Fourier Transformed Infrared Analysis (FTIR).
They won’t be foreign very much longer per company plans to move to the US.
By the book. 6k released to backup investor updates. Solid communication. Solid company. Pretty soon these will be 8k’s as the company plans on moving the Israeli operations to the US. it’s public information. DD. Know what you own and good luck.
https://ir.stockpr.com/todosmedical/sec-filings-email/content/0001493152-20-006634/form6-k.htm
Respectlully disagree. Nothing is ruined. This is still a promising company with promising future. Buy and hold IMHO
New Todos Medical, independent Director Dr. Lauren Chung is also on the board of "CURE Pharmaceutical" OTCQB $2.31
https://curepharmaceutical.com/about/board-of-directors
Lauren Chung, Ph.D
Director
Dr. Lauren Chung is the founder and CEO of MINLEIGH LLC, identifying, evaluating and partnering with companies for investments and various strategic, operational, and commercial opportunities. Dr. Chung has 20 years of healthcare investment management, investment banking, and advisory experience. Dr. Chung was a Managing Director in Healthcare Research at WestPark Capital. Previously, Dr. Chung was a Co-Founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital, and Pequot Capital. Earlier in her career, Dr. Chung was a recognized research scientist conducting cutting edge research in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung has published many leading peer-reviewed scientific journals. Dr. Chung serves as a board member in healthcare companies. Dr. Chung holds a Ph.D. in Neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
https://investor.todosmedical.com/news-events/press-releases/detail/48/todos-medical-appoints-dr-lauren-chung-to-its-board-of
$TOMDF Currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Orot has a proven track record of over 3 decades developing breakthrough technologies which will significantly impact cancer care.
$TOMDF Currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Orot has a proven track record of over 3 decades developing breakthrough technologies which will significantly impact cancer care. pic.twitter.com/nIav0OwWw0
— Randylus (@randylus) April 16, 2020
Chill please do your DD and read the recent 6k
It’s in the filings.
.20 going into May gives us $5 with a 1:25 RS. Up list to Nasdaq CM likely. Stick around. Good things coming. Don’t worry about dilution. CEO is aware of convertibles and is working on reducing the impact. Check @G_Commish on twitter. Know what you own and good luck.
$TOMDF #bullish close @Barchart https://t.co/OeQxg9BtTW pic.twitter.com/MhQUuHN6Yl
— Randylus (@randylus) April 15, 2020
$TOMDF Investor and Corporate Contact: Kim Sutton Golodetz - LHA Investor Relations, Senior Vice President
(212) 838-3777 kgolodetz@lhai.com
$TOMDF Investor and Corporate Contact: Kim Sutton Golodetz - LHA Investor Relations, Senior Vice President
— Randylus (@randylus) April 15, 2020
(212) 838-3777 kgolodetz@lhai.com pic.twitter.com/Pm9sXjjlEF
May 11th Nasdaq Capital Markets. Get ready.
More for me.
Shorts covered. Ready to fly. IMHO
Oh my bad. He’s talking about the MM.
wrong board
How those .10s looking now?
$TOMDF Todos Medical Achieves Medical Importer Status with US FDA finance.yahoo.com/news/todos-med… via @YahooFinance
$TOMDF Todos Medical Achieves Medical Importer Status with US FDA https://t.co/Hm04Fk37qU via @YahooFinance
— Randylus (@randylus) April 15, 2020
Passive investor SIH knows exactly what they are getting into. Seeking ownership of over 45% of the companies shares. They also stipulate in the 6k that todos must up list to the broader markets for the Provista close. They already over I’ve 30 million common shares. You can bet they aren’t sell today. Good luck.
Being transparent and successful is sneaky? We’ll be fine. Hope you do well.
Yes. I do think there will be retail selling but those that can see the big picture here should be rewarded. If they can wait. My self included. I didn’t bet the farm but nobody like to lose money either. Good luck.
So what size lot are you selling to me? Just curious.
From Proxy; It is important to note that one condition to the closing of the Provista transaction is the uplisting of the Company’s ordinary shares to a national securities exchange. The approval of the issuance of ordinary shares to SIH requires the affirmative vote of a majority of the shares present and voting at the Meeting (in person or by proxy). The Company is not aware that any of its officers, directors or interested party shareholders has a personal interest in the Provista transaction.
Your welcome. I really like Todos because they are so transparent. I really believe in their intent and they have a global footprint. It’s not going to happen overnight but, I have studied everything from med tech docs to financials for weeks. The share price will reflect the companies efforts and I believe we will get good news to solidify the benefits in the coming days and weeks. GLTA
It’s refreshing to see the discussion proceeding in the right direction. Common shareholders will vote this in. If people sell, I will buy.
While many companies that perform a reverse split continue to be dismal investments, some that turned out to work out very well were Priceline, Laboratory Corp. of America, Corrections Corp. of America, Titanium Metals, Raytheon, and Intuitive Surgical.
See ((( )))
Concluding that a reverse stock split guarantees investors (shareholders) will ultimately lose the value of their investment isn’t correct.
It’s true that many reverse stock splits are declared by companies whose share price has declined significantly due to bad news, failing financials, or bleak prospects for the company’s future success. (((this is NOT TOMDF)))
Reverse stock splits may be proposed and make sense when offering a stock tender during an acquisition of another firm. ((((((this IS TOMDF))))))
The key is to do your homework. Reverse splits have a fairly negative reputation, but if the underlying company is fundamentally healthy, (((this IS TOMDF))) it may present an opportunity if other investors are getting out and driving the price down.
From the 6k;
Purpose of the Reverse Share Split
In addition, the Company believes that the reverse share split will allow for a possible listing of the ordinary shares of the Company on The Nasdaq Capital Market, which requires a minimum bid price of $4.00 per share. The Company believes that the listing of the Company’s shares on The Nasdaq Capital Market will enable the Company to maintain greater access to the public capital markets and will afford the Company’s shareholders greater liquidity with respect to their holdings in the Company.
Yeah this wasn't in the filings "RS (wipe out current share holders)" -
Concluding that a reverse stock split guarantees investors (shareholders) will ultimately lose the value of their investment isn’t correct. It’s true that many reverse stock splits are declared by companies whose share price has declined significantly due to bad news, failing financials, or bleak prospects for the company’s future success.
Reverse stock splits may be proposed and make sense when offering a stock tender during an acquisition of another firm.
The key is to do your homework. Reverse splits have a fairly negative reputation, but if the underlying company is fundamentally healthy, it may present an opportunity if other investors are getting out and driving the price down.
Know what you own!
This is a proxy the shareholders will vote on. The shareholders will vote on what’s in their best interest. If your not a shareholder then you have no worries. Nasdaq capital markets will be next if we get the share price over $4.00 and meet the other less stringent requirements of the capital market.
In addition, the Company believes that the reverse share split will allow for a possible listing of the ordinary shares of the Company on The Nasdaq Capital Market, which requires a minimum bid price of $4.00 per share.
In addition, the Company believes that the reverse share split will allow for a possible listing of the ordinary shares of the Company on The Nasdaq Capital Market, which requires a minimum bid price of $4.00 per share. pic.twitter.com/Po2q38q7Rp
— Randylus (@randylus) April 14, 2020